{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:51Z","timestamp":1792786071425,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Imagine an Answer Foundation"},{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Giant Food Foundation"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011566","name":"Sidney Kimmel Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["CA006973"],"award-info":[{"award-number":["CA006973"]}],"id":[{"id":"10.13039\/100011566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor. Many patients with unresectable or recurrent\/refractory tumors have significant lifelong disability. The majority of pLGG have mutations increasing the activity of the Ras\/mitogen-activated protein kinase (MAPK) pathway. Activation of mammalian target of rapamycin (mTOR) is also a hallmark of pLGG. We therefore hypothesized that the dual target of rapamycin complexes 1 and 2 (TORC1\/2) kinase inhibitor TAK228 would synergize with the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in pLGG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested TAK228 and trametinib in patient-derived pLGG cell lines harboring drivers of pLGG including BRAFV600E and neurofibromatosis type 1 loss. We measured cell proliferation, pathway inhibition, cell death, and senescence. Synergy was analyzed via MTS assay using the Chou\u2013Talalay method. In vivo, we tested for overall survival and pathway inhibition and performed immunohistochemistry for proliferation and vascularization. We performed a scratch assay and measured angiogenesis protein activation in human umbilical vein endothelial cells (HUVECs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TAK228 synergized with trametinib in pLGG at clinically relevant doses in all tested cell lines, suppressing proliferation, inducing apoptosis, and causing senescence in a cell line\u2013dependent manner. Combination treatment increased median survival by 70% and reduced tumor volume compared with monotreatment and control cohorts. Vascularization of tumors decreased as measured by CD31 and CD34. Combination treatment blocked activation of focal adhesion kinase (FAK) and sarcoma proto-oncogene non-receptor tyrosine kinase (SRC) in HUVEC cells and reduced HUVEC migration compared with each drug alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of TAK228 and trametinib synergized to suppress the growth of pLGG. These agents synergized to reduce tumor vascularity and endothelial cell growth and migration by blocking activation of FAK and SRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noz230","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T15:08:57Z","timestamp":1576336137000},"page":"563-574","source":"Crossref","is-referenced-by-count":33,"title":["Synergistic activity of mTORC1\/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-4745","authenticated-orcid":false,"given":"Antje","family":"Arnold","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yuan","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antionette","family":"Price","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Harris","sequence":"first","affiliation":[{"name":"Johns Hopkins University Krieger School of Arts and Sciences, Department of Molecular and Cell Biology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G","family":"Eberhart","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H","family":"Raabe","sequence":"first","affiliation":[{"name":"Johns Hopkins School of Medicine, Department of Pathology, Division of Neuropathology, Baltimore, Maryland"},{"name":"Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Division of Pediatric Oncology, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"5","key":"2020041508253509500_CIT0001","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Invest."},{"issue":"9","key":"2020041508253509500_CIT0002","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/NEN.0b013e3181845622","article-title":"Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma","volume":"67","author":"Bar","year":"2008","journal-title":"J Neuropathol Exp Neurol."},{"issue":"3","key":"2020041508253509500_CIT0003","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00401-010-0784-9","article-title":"PI3K\/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma","volume":"121","author":"Rodriguez","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2020041508253509500_CIT0004","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/neuonc\/not132","article-title":"Activation of mTORC1\/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target","volume":"15","author":"H\u00fctt-Cabezas","year":"2013","journal-title":"Neuro Oncol."},{"issue":"17","key":"2020041508253509500_CIT0005","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1158\/1078-0432.CCR-13-0662","article-title":"New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model","volume":"19","author":"Raabe","year":"2013","journal-title":"Clin Cancer Res."},{"key":"2020041508253509500_CIT0006","first-page":"2251","article-title":"Trametinib: a MEK inhibitor for management of metastatic melanoma","volume":"8","author":"Lugowska","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"18","key":"2020041508253509500_CIT0007","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med."},{"issue":"2","key":"2020041508253509500_CIT0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11060-018-2971-9","article-title":"Trametinib for progressive pediatric low-grade gliomas","volume":"140","author":"Kondyli","year":"2018","journal-title":"J Neurooncol."},{"key":"2020041508253509500_CIT0009","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/neuonc\/nou208.15","article-title":"Final results of a prospective mult-institutional phase II study of everolimus (RAD001), an mTOR inhibitor, in pediatric recurrent or progressive low-grade glioma. A POETIC consortium trial","volume":"16","author":"Kieran","year":"2014","journal-title":"Neuro Oncol."},{"issue":"2","key":"2020041508253509500_CIT0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/neuonc\/noy150","article-title":"Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin","volume":"21","author":"Poore","year":"2019","journal-title":"Neuro Oncol."},{"issue":"10","key":"2020041508253509500_CIT0011","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/neuonc\/nox067","article-title":"The TORC1\/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity","volume":"19","author":"Rubens","year":"2017","journal-title":"Neuro Oncol."},{"issue":"4","key":"2020041508253509500_CIT0012","doi-asserted-by":"crossref","first-page":"e5209","DOI":"10.1371\/journal.pone.0005209","article-title":"Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development","volume":"4","author":"Bax","year":"2009","journal-title":"PLoS One."},{"issue":"7","key":"2020041508253509500_CIT0013","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1158\/1078-0432.CCR-04-2045","article-title":"O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines","volume":"11","author":"Bobola","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2020041508253509500_CIT0014","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.22576","article-title":"Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program","volume":"55","author":"Kolb","year":"2010","journal-title":"Pediatr Blood Cancer."},{"issue":"24","key":"2020041508253509500_CIT0015","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1158\/1078-0432.CCR-13-0842","article-title":"Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma","volume":"19","author":"Bid","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2020041508253509500_CIT0016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"2020041508253509500_CIT0017","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.18632\/oncotarget.3078","article-title":"Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target","volume":"6","author":"Weingart","year":"2015","journal-title":"Oncotarget."},{"issue":"5","key":"2020041508253509500_CIT0018","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"An introduction to the wound healing assay using live-cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adh Migr."},{"issue":"2","key":"2020041508253509500_CIT0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/NEN.0000000000000161","article-title":"The chromatin-modifying protein HMGA2 promotes atypical teratoid\/rhabdoid cell tumorigenicity","volume":"74","author":"Kaur","year":"2015","journal-title":"J Neuropathol Exp Neurol."},{"issue":"11","key":"2020041508253509500_CIT0020","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-10-3349","article-title":"BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model","volume":"17","author":"Raabe","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2020041508253509500_CIT0021","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/neuonc\/nos077","article-title":"Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas","volume":"14","author":"Horbinski","year":"2012","journal-title":"Neuro Oncol."},{"issue":"12","key":"2020041508253509500_CIT0022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/emmm.201000106","article-title":"Endothelial FAK is required for tumour angiogenesis","volume":"2","author":"Tavora","year":"2010","journal-title":"EMBO Mol Med."},{"issue":"6","key":"2020041508253509500_CIT0023","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","article-title":"Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability","volume":"4","author":"Eliceiri","year":"1999","journal-title":"Mol Cell."},{"issue":"15","key":"2020041508253509500_CIT0024","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-15-3011","article-title":"DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets","volume":"22","author":"Hanaford","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"15","key":"2020041508253509500_CIT0025","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2020041508253509500_CIT0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10010023","article-title":"mTOR cross-talk in cancer and potential for combination therapy","volume":"10","author":"Conciatori","year":"2018","journal-title":"Cancers."},{"issue":"2","key":"2020041508253509500_CIT0027","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.theriogenology.2015.09.020","article-title":"ROCK inhibitor Y27632 promotes proliferation and diminishes apoptosis of marmoset induced pluripotent stem cells by suppressing expression and activity of caspase 3","volume":"85","author":"Wu","year":"2016","journal-title":"Theriogenology."},{"issue":"23","key":"2020041508253509500_CIT0028","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1002\/cncr.30909","article-title":"Probing the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in gliomas: a phase 2 study of everolimus for recurrent adult low-grade gliomas","volume":"123","author":"Wahl","year":"2017","journal-title":"Cancer."},{"issue":"1","key":"2020041508253509500_CIT0029","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/1535-7163.MCT-15-0170","article-title":"Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma","volume":"15","author":"Bridgeman","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"2020041508253509500_CIT0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pbc.24297","article-title":"Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas","volume":"60","author":"Hwang","year":"2013","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2020041508253509500_CIT0031","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1541-7786.MCR-18-0923","article-title":"Novel oral mTORC1\/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3K\u03b1 inhibitor TAK-117 in preclinical bladder cancer models","volume":"17","author":"Hern\u00e1ndez-Prat","year":"2019","journal-title":"Mol Cancer Res."},{"issue":"3","key":"2020041508253509500_CIT0032","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell."},{"issue":"4","key":"2020041508253509500_CIT0033","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.24300","article-title":"TAK-228 (formerly MLN0128), an investigational oral dual TORC1\/2 inhibitor: a phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"91","author":"Ghobrial","year":"2016","journal-title":"Am J Hematol."},{"issue":"2","key":"2020041508253509500_CIT0034","doi-asserted-by":"crossref","first-page":"e000291","DOI":"10.1136\/esmoopen-2017-000291","article-title":"Phase I study of the investigational oral mTORC1\/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours","volume":"3","author":"Moore","year":"2018","journal-title":"ESMO Open."},{"issue":"21","key":"2020041508253509500_CIT0035","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1158\/1078-0432.CCR-15-1101","article-title":"BRAF status in personalizing treatment approaches for pediatric gliomas","volume":"22","author":"Olow","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"19","key":"2020041508253509500_CIT0036","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med."},{"issue":"2","key":"2020041508253509500_CIT0037","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol."},{"issue":"49","key":"2020041508253509500_CIT0038","doi-asserted-by":"crossref","first-page":"84697","DOI":"10.18632\/oncotarget.20949","article-title":"Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K\/mTOR signaling pathways","volume":"8","author":"Jain","year":"2017","journal-title":"Oncotarget."},{"issue":"6","key":"2020041508253509500_CIT0039","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/neuonc\/nou329","article-title":"Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noz230\/31826037\/noz230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/4\/563\/33047106\/noz230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/4\/563\/33047106\/noz230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T08:26:01Z","timestamp":1586939161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/4\/563\/5679447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,16]]},"published-print":{"date-parts":[[2020,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz230","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,12,16]]}}}